Policy | August 03, 2021
Drug exports grow on the back of govt support
Drug formulations and biologics make impressive gains
Drug formulations and biologics make impressive gains
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The group now has 320 approvals and has so far filed over 400 ANDAs
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The first batch will be shipped to the Gamaleya Center for the quality control
Subscribe To Our Newsletter & Stay Updated
